LEON J. ROBINSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
In 1935 Prinzmetal and Bloomberg1 introduced benzedrine (phenylisopropylamine), a comparatively new sympathomimetic for the treatment of narcolepsy. Its dramatic success in this condition stimulated many investigations of additional therapeutic indications for the use of the systemic effects of benzedrine, as well as verification of its value in narcolepsy.2 It has been demonstrated that benzedrine relaxes gastrointestinal spasm3; ameliorates apathy and depression in normals and in neurotic persons,4 and in post-encephalitic Parkinsonism5; aborts marked drop in blood pressure during spinal anesthesia6; and prevents syncope caused by orthostatic hypotension.7 We have found it efficacious in the prevention of carotid sinus syncope of
ROBINSON LJ. TOLERANCE TO BENZEDRINE SULFATE1. Ann Intern Med. 1938;12:255–258. doi: 10.7326/0003-4819-12-2-255
Download citation file:
Published: Ann Intern Med. 1938;12(2):255-258.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use